About Adaptive Phage Therapeutics
Adaptive Phage Therapeutics is a company based in Bethesda (United States) founded in 2016 was acquired by BiomX in March 2024. Adaptive Phage Therapeutics has raised $107.87 million across 11 funding rounds from investors including Amgen, Lilly and Bayer. The company has 78 employees as of December 31, 2022. Adaptive Phage Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
- Headquarter Bethesda, United States
- Employees 78 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adaptive Phage Therapeutics
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Adaptive Phage Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has successfully raised a total of $107.87M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Lilly and Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in antimicrobial resistance treatment development.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated by Mayo Clinic Business Accelerator.
|
Locked | Locked | Locked |
Investor details for Adaptive Phage Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adaptive Phage Therapeutics
Investment portfolio details for Adaptive Phage Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adaptive Phage Therapeutics
Detailed financials for Adaptive Phage Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adaptive Phage Therapeutics Comparisons
Peer comparison for Adaptive Phage Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adaptive Phage Therapeutics
Adaptive Phage Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Microbiome therapeutics are developed for dysbiosis-linked diseases.
|
Detailed competitors of Adaptive Phage Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adaptive Phage Therapeutics
Complete news archive for Adaptive Phage Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adaptive Phage Therapeutics
Adaptive Phage Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Adaptive Phage Therapeutics is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Adaptive Phage Therapeutics is a funded company, having raised a total of $107.87M across 11 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Adaptive Phage Therapeutics is 78.
Adaptive Phage Therapeutics was founded in 2016 and is based in Bethesda, United States. Operations focus on the biotechnology sector, where therapies for multi-drug resistant bacterial infections are provided through PhageBanking, a collection of targeted bacteriophages. A rapid matching system pairs phages with patient-specific infections. Success in a first-in-human case involving Acinetobacter baumannii has been achieved, supporting patient survival.
Adaptive Phage Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Adaptive Phage Therapeutics has 12 investors. Key investors include Amgen, Lilly, Bayer, ARE, and Mayo Clinic.